Adverse Events Associated With Outcomes in PD-1/PD-L1–Treated Urothelial Carcinoma
An FDA pooled analysis suggests that certain AEs were associated with response and overall survival in PD-1/PD-L1-treated urothelial cancer.
All articles by Andrea S. Blevins Primeau, PhD, MBA
Jury Still Out on Whether Immunotherapy Can Cure Metastatic RCC
Though uncommon, complete responses are seen among patients with metastatic disease, but CRs seem to occur more often with immune checkpoint inhibitors.
BRCA2 Mutations Tied With Poor Survival, Progression in mCRPC
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Next post in Prostate Cancer
